1. Home
  2. CRNX vs WAY Comparison

CRNX vs WAY Comparison

Compare CRNX & WAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$42.21

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Waystar Holding Corp.

WAY

Waystar Holding Corp.

HOLD

Current Price

$23.55

Market Cap

3.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
WAY
Founded
2008
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.8B
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
CRNX
WAY
Price
$42.21
$23.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
17
Target Price
$76.75
$36.59
AVG Volume (30 Days)
1.3M
2.7M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
569.23
EPS
N/A
0.22
Revenue
$1,039,000.00
$1,099,278,000.00
Revenue This Year
$720.10
$18.26
Revenue Next Year
$184.67
$10.62
P/E Ratio
N/A
$106.57
Revenue Growth
N/A
16.50
52 Week Low
$25.83
$17.26
52 Week High
$57.99
$39.99

Technical Indicators

Market Signals
Indicator
CRNX
WAY
Relative Strength Index (RSI) 71.81 70.18
Support Level $38.68 $21.03
Resistance Level $44.89 $26.73
Average True Range (ATR) 1.71 0.91
MACD 0.74 0.56
Stochastic Oscillator 97.89 96.27

Price Performance

Historical Comparison
CRNX
WAY

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About WAY Waystar Holding Corp.

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

Share on Social Networks: